Skip to main content

A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase ? Chronic Myelogenous Leukemia (ASC2ESCALATE)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

May 25, 2023

End Date

July 30, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

May 25, 2023

End Date

July 30, 2027